Pen Needles Market Size & Growth Forecast 2027–2036, By Segments (Product, Distribution Channel, Application, Length, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Pen Needles Market size was assessed at USD 2.97 Billion in 2026 and is poised to grow at 11.02% CAGR between 2027 and 2036, surpassing USD 8.45 Billion by 2036. The industry revenue for 2027 is estimated at USD 3.25 Billion.
Get more details on this report
Request Free Sample ReportPen Needles Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 44.2% revenue share in 2026, supported by widespread injectable therapy use, established diabetes care, and demand for convenient self-administration.
- Expanding healthcare infrastructure, rising diabetes-management awareness, increased healthcare spending, and wider access to modern medical devices are supporting self-injection adoption.
Segment Momentum
- Standard pen needles held 83.99% of the market in 2026 due to widespread use in routine insulin administration, broad device compatibility, ease of handling, and strong acceptance among healthcare professionals and patients.
- The GLP-1 application segment is expanding rapidly as use of GLP-1 therapies increases, supported by broader adoption of injectable treatments, continued innovation, and rising patient acceptance of pen-based drug delivery systems.
Market Expansion Drivers
- Rising diabetes prevalence driving sustained demand for insulin delivery devices
- Growing geriatric population increasing chronic injectable medication usage
- Expanding home-based diabetes management accelerating self-injection device adoption
Leading Market Participants
- Major players in the pen needles market include Becton, Dickinson and Company (USA), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Terumo Corporation (Japan), B. Braun Melsungen AG (Germany), Owen Mumford Ltd. (United Kingdom), Embecta Corp. (USA), HTL-STREFA S.A. (Poland), Nipro Corporation (Japan), Artsana Group (Italy)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 2.97 Billion
- 2027 Estimated Market Size: USD 3.25 Billion
- Projected Market Size: USD 8.45 Billion by 2036
- Growth Forecast: 11.02% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Standard Pen Needles (Product) | Retail Pharmacies (Distribution Channel) | Insulin (Application) | 8 Mm (Length) | Home Care Settings (End-use)
- Emerging Opportunity Segment: Safety Pen Needles (Product) | Online Channels (Distribution Channel) | Glucagon-like-Peptide-1 (GLP-1) (Application) | 4 Mm (Length) | Home Care Settings (End-use)
Market Growth Drivers and Industry Trends
Rising diabetes prevalence driving sustained demand for insulin delivery devices
The increasing number of individuals diagnosed with diabetes is creating long-term demand for effective insulin administration solutions, which will drive the pen needles market growth. As diabetes management often requires regular insulin therapy, healthcare providers and patients continue to rely on pen-based delivery systems that offer convenience, dosing accuracy, and ease of use compared with traditional injection methods. Greater emphasis on early diagnosis, continuous disease management, and improved treatment adherence further supports consistent consumption of pen needles across both healthcare facilities and homecare settings. The need for comfortable and reliable injection experiences also encourages ongoing product development focused on patient convenience.
Growing geriatric population increasing chronic injectable medication usage
An aging global population is contributing to higher incidence of chronic conditions requiring injectable therapies, enabling the pen needles market to expand alongside evolving healthcare needs. Older adults frequently require long-term treatment for diseases that necessitate routine self-administration or caregiver-assisted injections, increasing demand for pen needles designed to improve usability and patient comfort. Ergonomic designs, reduced injection discomfort, and compatibility with a variety of medication pens are becoming increasingly important as healthcare systems seek to support aging populations managing multiple chronic illnesses outside institutional care settings.
Expanding home-based diabetes management accelerating self-injection device adoption
The growing preference for home-based treatment is transforming diabetes care delivery, and this trend will propel the pen needles market growth by encouraging wider adoption of self-injection devices. Patients increasingly manage their condition independently using insulin pens that simplify daily treatment routines while reducing dependence on frequent clinical visits. Healthcare providers also support home-based care by promoting patient education, self-monitoring, and user-friendly injection technologies that improve treatment compliance. Demand continues to increase for pen needles that offer consistent performance, minimal discomfort, and compatibility with modern insulin delivery systems used in routine homecare.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising diabetes prevalence driving sustained demand for insulin delivery devices | 2.2% | High | North America, Asia Pacific | High | Near Term |
| Growing geriatric population increasing chronic injectable medication usage | 1.8% | Moderate | Europe, North America | High | Near Term |
| Expanding home-based diabetes management accelerating self-injection device adoption | 1.5% | Low | North America, Asia Pacific | High | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Pen needles market was led by North America, which accounted for the largest revenue share of 44.2% in 2026. The region’s strong position is supported by widespread adoption of injectable therapies, a well-established diabetes care infrastructure, and high demand for convenient drug-delivery solutions. Greater emphasis on self-administration and patient comfort is encouraging the use of pen-based delivery systems, while established healthcare systems and favorable access to advanced medical devices continue to support market penetration. The growing focus on safer and more user-friendly injection practices also reinforces demand for pen needles across clinical and home-care settings.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to be the fastest-growing regional market, supported by expanding healthcare infrastructure, increasing awareness of diabetes management, and the rising adoption of self-injection therapies. Growing healthcare expenditure and improved access to modern medical devices across emerging economies are creating favorable conditions for pen needle uptake. In addition, increasing efforts to improve chronic disease management and expand treatment accessibility are encouraging the adoption of convenient injectable drug-delivery technologies across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Patient-Centered DeliveryThe U.S. market prioritizes pen needles that improve patient comfort, encourage treatment adherence, and support self-administered diabetes care. Healthcare providers increasingly favor products compatible with multiple injection devices while reducing discomfort during routine insulin administration.
Germany 🇩🇪
Quality-Driven Device AdoptionGermany focuses on high-quality pen needles that deliver precise drug administration and consistent clinical performance. The market values products meeting rigorous regulatory expectations while supporting expanding home-based diabetes management across diverse patient populations.
Japan 🇯🇵
Comfort-Oriented InnovationJapan emphasizes pen needles with ultra-thin designs that reduce injection discomfort and improve the user experience for long-term diabetes management. Manufacturers continue refining product ergonomics and compatibility with modern insulin delivery systems used throughout the country.
South Korea 🇰🇷
Smart Diabetes Care AlignmentSouth Korea increasingly adopts pen needles that complement connected diabetes management solutions and modern insulin delivery practices. The market favors reliable products that support convenient self-care while aligning with expanding digital healthcare adoption.
France 🇫🇷
Home Care OptimizationFrance continues to expand demand for pen needles that simplify insulin administration outside clinical settings. The country prioritizes safe, easy-to-use products that enhance patient confidence while supporting long-term chronic disease management programs.
Italy 🇮🇹
Accessible Diabetes ManagementItaly supports steady demand for pen needles through broader adoption of convenient insulin delivery options in outpatient care. The market values dependable products that balance ease of use, consistent injection performance, and compatibility with commonly prescribed insulin pens.
Segment Leadership and Growth Trends
Pen Needles Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Standard Pen Needles (Largest Segment) vs Safety Pen Needles (Fastest-Growing Segment)
The standard pen needles segment dominated the pen needles market, accounting for 83.99% of the market share in 2026. Its leadership is supported by widespread use in routine insulin administration, broad compatibility with commonly prescribed insulin delivery devices, and strong acceptance among healthcare professionals and patients. Standard pen needles remain the preferred option due to their established clinical use, ease of handling, and availability across healthcare settings, ensuring continued demand for daily diabetes management.
Safety pen needles represent the fastest-growing product segment as healthcare providers place greater emphasis on reducing accidental needlestick injuries and improving user protection. Increasing adoption of safety-engineered medical devices, strengthened workplace safety requirements, and rising awareness of infection prevention are encouraging broader utilization across hospitals, clinics, and home healthcare environments. Growing focus on patient and caregiver safety is expected to further accelerate demand for this segment.
Distribution Channel Segment Analysis: Retail Pharmacies (Largest Segment) vs Online Channels (Fastest-Growing Segment)
Retail pharmacies held the largest share of 60.53% in 2026, supported by their extensive accessibility and established role in dispensing diabetes care products. Patients frequently rely on these pharmacies for convenient access to prescription refills, professional guidance, and a consistent supply of pen needles. Strong distribution networks and trusted pharmacist support continue to reinforce the segment's leading position.
The pen needles market is witnessing the fastest growth in online channels as digital healthcare adoption continues to expand. Consumers increasingly value the convenience of home delivery, competitive pricing, and simplified reordering for chronic disease management products. The growing penetration of e-commerce platforms and digital pharmacy services, combined with rising patient preference for remote purchasing options, is contributing to the rapid expansion of this distribution channel.
Application Segment Analysis: Insulin (Largest Segment) vs Glucagon-like-Peptide-1 (GLP-1) (Fastest-Growing Segment)
The insulin application segment accounted for the largest share of 80.36% in 2026, reflecting the long-established use of insulin therapy in diabetes management worldwide. Consistent treatment requirements among insulin-dependent patients generate sustained demand for pen needles, while ongoing emphasis on effective glycemic control continues to support widespread adoption. The extensive availability of insulin pen systems further strengthens the segment's dominant position.
The pen needles market is also experiencing strong momentum from the glucagon-like-peptide-1 (GLP-1) application segment, which is the fastest-growing area of use. Increasing utilization of GLP-1 therapies for diabetes management and broader clinical adoption of injectable treatment options are driving demand for compatible pen needles. Continued innovation in injectable therapies and expanding patient acceptance of pen-based drug delivery systems are expected to support sustained growth in this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Standard Pen Needles, Safety Pen Needles | Standard Pen Needles | Safety Pen Needles |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Channels | Retail Pharmacies | Online Channels |
| Application | Insulin, Glucagon-like-Peptide-1 (GLP-1), Growth Hormone, Others | Insulin | Glucagon-like-Peptide-1 (GLP-1) |
| Length | 4 Mm,5 Mm,6 Mm,8 Mm,10 Mm,12 Mm | 8 Mm | 4 Mm |
| End-use | Hospitals and Clinics, Home Care Settings, Others | Home Care Settings | Home Care Settings |
Competitive Landscape and Market Positioning
Major players in the pen needles market:
- Becton Dickinson and Company (USA)
- Novo Nordisk A/S (Denmark)
- Ypsomed Holding AG (Switzerland)
- Terumo Corporation (Japan)
- B. Braun Melsungen AG (Germany)
- Owen Mumford Ltd. (United Kingdom)
- Embecta Corp. (USA)
- HTL-STREFA S.A. (Poland)
- Nipro Corporation (Japan)
- Artsana Group (Italy)
Product differentiation in the pen needles market is increasingly centered on improving patient comfort without compromising dosing accuracy, encouraging manufacturers to refine needle geometry, surface treatments, and injection performance. As self-administration becomes more common across chronic disease management, competition is expanding beyond basic consumables toward solutions that promote adherence through easier handling and more consistent user experience. Suppliers are also responding to evolving healthcare procurement preferences by balancing clinical performance with manufacturing efficiency and dependable supply, reinforcing the importance of quality assurance alongside product innovation.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Becton Dickinson and Company (USA) | |||||||
| Novo Nordisk A/S (Denmark) | |||||||
| Ypsomed Holding AG (Switzerland) | |||||||
| Terumo Corporation (Japan) | |||||||
| B. Braun Melsungen AG (Germany) | |||||||
| Owen Mumford Ltd. (United Kingdom) | |||||||
| Embecta Corp. (USA) | |||||||
| HTL-STREFA S.A. (Poland) | |||||||
| Nipro Corporation (Japan) | |||||||
| Artsana Group (Italy) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Ascensia Diabetes Care | Jun-26 | Ascensia Diabetes Care, a business unit of PHC Holdings, expanded its specialized diabetes management portfolio through the commercial launch of Contour Comfort pen needles. The introduction represents a strategic effort to broaden the company's product line in insulin delivery consumables and capture market share in pen-based injection therapies. |
| Embecta | Mar-26 | Embecta entered a definitive agreement to acquire medical device manufacturer Owen Mumford for up to $201 million. The transaction aligns with Embecta’s broader strategic diversification roadmap to expand beyond its core insulin delivery solutions and establish a stronger footprint in broader drug-delivery and advanced medical device sectors. |
| Trividia Health | Aug-25 | Trividia Health introduced its TRUEplus five-bevel insulin pen needle product range into the United Kingdom market. The geographic expansion strengthens the company's international distribution footprint and enhances the availability of its injection consumables portfolio within the competitive British diabetes care ecosystem. |
| Owen Mumford | Apr-25 | Owen Mumford introduced its Unifine OTC Pen Needles, targeting the direct cash-pay pharmacy segment. The strategic launch provides an affordable, non-reimbursed purchasing path for healthcare consumers, expanding the company’s retail distribution channel accessibility for critical insulin delivery consumables. |
| Ypsomed | Aug-24 | Ypsomed finalized the divestiture of its pen needle and blood glucose monitoring businesses to medical technology firm MTD. This strategic divestment allows Ypsomed to reallocate its focus and operational resources exclusively toward scaling its expanding insulin pump operations, while transferring its pen needle assets to a specialized sector player. |
| HTL-Strefa Inc. | Mar-24 | HTL-Strefa expanded its medical consumables footprint in North America by commercializing the Sicura passive safety needle. The launch addresses growing regulatory and clinical focus on healthcare safety by delivering a safety-engineered mechanism designed to prevent needlestick injuries, reinforcing the company's regional competitive position. |
| Terumo India | Sep-22 | Terumo India expanded its regional injection therapy portfolio through the market launch of FineGlide, a sterile, three-bevel ultra-sharp pen needle coated with high-grade silicone. The launch enhances the company's competitive positioning in the Indian subcontinent by offering advanced structural design aimed at improving patient comfort during self-medication. |
| BD | Jan-19 | BD secured FDA approval for its second-generation BD Nano pen needle, designed to optimize subcutaneous injection depth consistency. This regulatory milestone allows the company to commercialize a highly differentiated consumable that improves drug administration accuracy for diabetes patients, elevating its technology standard in the market. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pen Needles Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Device Compatibility | Universal-Compatible Pen Needles, Brand-Specific Compatible Pen Needles |
| User Setting | Professional-Administered Use, Home Self-Administration, Caregiver-Administered Use |
| Purchase Volume | Individual/Small-Pack Purchases, Standard Multi-Pack Purchases, Bulk/Institutional Purchases |
Pen Needles Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Patient-Centric Device Preferences |
|
| Injection Safety Adoption Strategies |
|
| Home-Based Injection Care Evolution |
|
Need a different cut of the data?
Request Custom ResearchHow big is the pen needles market?
How will the pen needles industry grow in terms of size and CAGR by 2036?
How is the shift toward home-based diabetes management influencing demand for pen needles?
Why is long-term diabetes management sustaining growth in the pen needles market?
Why do standard pen needles lead the pen needles market?
Why is the GLP-1 application segment growing fastest in the pen needles market?
Why does North America lead the pen needles market?
What is driving pen needles market growth in Asia Pacific?
Who are the major participants shaping the pen needles landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization